MB 6
Alternative Names: MB-6Latest Information Update: 23 Aug 2022
At a glance
- Originator MICROBIO Group
- Class Phytotherapies
- Mechanism of Action Antioxidants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 23 Aug 2022 Discontinued - Phase-III for Colorectal cancer (Late-stage disease, Adjuvant therapy) in Taiwan (PO)
- 11 Oct 2021 MB 6 is still in phase III trials for Colorectal cancer in Taiwan (NCT02135887)
- 12 Jun 2018 MB 6 is still in phase III trials for Colorectal cancer in Taiwan (MicroBio Group pipeline, June 2018)